Fate Therapeutics (FATE) Amortizatization of Intangibles (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Amortizatization of Intangibles came in at $772000.0 in Q1 2026, down 27.72% YoY from $1.1 million in Q1 2025, and down 12.37% on a QoQ basis from $881000.0 in Q4 2025.
Analysis
Fate Therapeutics (FATE) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 12 years of Amortizatization of Intangibles data on file, last reported at $772000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 27.72% year-over-year to $772000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 55.97% YoY) and the FY2025 annual result came in at $3.6 million, down 60.29% from the prior year.
- Amortizatization of Intangibles retreated to $772000.0 in Q1 2026, from $881000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $3.3 million in Q3 2023 to a low of -$873000.0 in Q1 2022.
- A 5-year average of $1.5 million and a median of $1.2 million in 2022 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles soared 696.33% — and 2025, when it slumped 68.89%.
- Tracing FATE's Amortizatization of Intangibles over 5 years: stood at $1.2 million in 2022, then jumped by 133.41% to $2.9 million in 2023, then plunged by 47.35% to $1.5 million in 2024, then tumbled by 42.42% to $881000.0 in 2025, then fell by 12.37% to $772000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $772000.0 (Q1 2026), $881000.0 (Q4 2025), and $810000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - | 764,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 764,000.00 |
| Mar 31, 2026 | 772,000.00 |
| Dec 31, 2025 | 881,000.00 |
| Sep 30, 2025 | 810,000.00 |
| Jun 30, 2025 | 847,000.00 |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 2.63 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Sep 30, 2023 | 3.26 Mn |
| Jun 30, 2023 | 2.94 Mn |
| Mar 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 409,000.00 |
| Jun 30, 2022 | -525,000.00 |
| Mar 31, 2022 | -873,000.00 |
| Dec 31, 2021 | -1.07 Mn |
| Sep 30, 2021 | -1.37 Mn |